Company Registration
NGO Registration
Virtual business address
Startup Registration
Shop Act Registration
Annual Compliance
Income tax Filing
Trade License Registration
BIS Registration main
CDSCO Registration
Star Rating Certification
WPC Registration
Brand Registration
Legal Metrology Certification
PESO certification
Factory License Registration
Fire NOC
AERB Certification
PSARA License
Fssai License
RCMC Certification
Import Export Registration
China Food Export
RNI Certification
NSIC Registration
ISO Certification Main
US FDA
ICEGATE Registration Main
CPCB Approval
EIA Environment
CPCB/SPCB
E-Waste Management
Plastic Waste Management
Battery Waste Management
Tue, Jul 28 2026
Raju Karn
India's pharmaceutical industry manufactures thousands of medicines under different brand names every year. While branding helps companies build market recognition, it has also created a challenge where different medicines are sold under similar or related brand names. In many cases, companies launch multiple products by adding suffixes such as DSR, AM, H, XT, or Forte to an existing brand. Although these medicines may contain different active ingredients and are used for different medical conditions, their similar names can sometimes create confusion among doctors, pharmacists, and patients.
To address this issue, the Central Drugs Standard Control Organisation (CDSCO) has issued a draft proposal seeking public comments on regulating the use of pharmaceutical brand name extensions. The proposal aims to reduce medication errors and improve patient safety by discouraging the use of the same or confusingly similar brand names for different drug formulations. Since this is currently a draft proposal, it has not yet become a final regulation. In this article, we explain what the proposal means, why it has been introduced, and how it may affect pharmaceutical companies if implemented.
CDSCO has released a draft proposal to regulate the use of pharmaceutical brand name extensions. The proposal has attracted attention because it seeks to prevent situations where medicines containing different active ingredients are marketed under the same or confusingly similar brand names. The regulator believes that clearer branding can help reduce medication errors and improve patient safety.
Today, many pharmaceutical companies use an existing brand name for multiple products by adding suffixes such as:
Although these medicines may have different compositions, healthcare professionals and patients may mistakenly assume that they belong to the same product family. Through this draft proposal, CDSCO intends to encourage a more transparent and consistent approach to pharmaceutical branding.
The primary objective of the proposal is to reduce confusion caused by similar medicine names. Medicines with almost identical brand names but different formulations can increase the possibility of prescribing or dispensing the wrong product, particularly in busy hospitals and pharmacies where healthcare professionals handle a large number of prescriptions every day.
For example:
By regulating the use of brand name extensions, CDSCO aims to improve medicine identification and promote safer use of pharmaceutical products across the healthcare system.
The "Same Brand – Different Drug" practice refers to using one established brand name for multiple medicines that contain different active pharmaceutical ingredients. Instead of creating a new brand for every formulation, companies sometimes extend an existing brand by adding different suffixes.
Although these products may appear to be related, they can contain completely different active ingredients and may be intended to treat different health conditions. This marketing strategy is commonly known as brand name extension. While it can strengthen brand recognition, it may also create confusion if healthcare professionals or patients assume that similarly named medicines contain the same formulation.
Medicine names are one of the first identifiers used by doctors, pharmacists, hospitals, and patients. When different formulations share nearly identical brand names, the possibility of confusion increases, particularly when medicines are prescribed, dispensed, or purchased under time-sensitive situations.
Some possible risks include:
The draft proposal has been introduced to reduce these risks by promoting clearer pharmaceutical branding and improving medicine identification throughout the healthcare system.
According to the CDSCO draft proposal, the regulator intends to improve the regulation of pharmaceutical brand name extensions to reduce medication errors and patient confusion. The proposal has been released for public consultation before any final decision is taken.
Some important highlights include:
The official notice primarily focuses on seeking stakeholder feedback, and any detailed implementation mechanism will become clearer if and when the proposal is finalized.
If the draft proposal is implemented, it could affect businesses involved in manufacturing, marketing, and selling branded medicines. Companies that currently use similar brand names for different formulations may need to review their branding strategy and future product launches to comply with the revised regulatory requirements.
The proposal may impact:
Since the proposal is still under consultation, pharmaceutical companies should monitor future CDSCO notifications and evaluate how the final framework may affect their existing and upcoming brands.
Although the proposal is still in the draft stage, pharmaceutical companies should start reviewing their existing brand portfolios and future branding strategies. Preparing early can help businesses avoid compliance issues if the proposal is finalized in its current or revised form. Companies launching new products should pay extra attention to brand selection to reduce the possibility of conflicts with existing medicines.
Businesses can consider taking the following steps:
Taking proactive measures now can help companies adapt more smoothly if the framework becomes part of the final regulatory requirements.
One of the biggest questions for pharmaceutical companies is whether existing brands will be affected. The current CDSCO notice mainly focuses on seeking public comments and does not provide detailed information regarding the treatment of already approved brand names. Any final decision regarding existing brands is likely to become clearer after the consultation process and publication of the final framework.
Companies that currently market multiple formulations under similar brand names should closely monitor future regulatory announcements. Businesses may eventually need to review their product portfolios, branding strategies, and future product approvals depending on how the final policy is implemented.
If implemented, the proposed framework could provide several benefits for both patients and the pharmaceutical industry. A more transparent and consistent brand naming system can improve medicine identification and reduce the possibility of confusion in healthcare settings.
Potential benefits may include:
By encouraging clearer branding practices, the proposal aims to strengthen confidence throughout the medicine supply chain.
While the proposal focuses on patient safety, pharmaceutical companies may also face practical challenges if new brand naming restrictions are introduced. Businesses that have invested heavily in building brand recognition may need to reconsider future branding approaches or review product portfolios for compliance.
Some possible challenges include:
Despite these challenges, many industry experts believe that a clearer brand naming system could ultimately reduce confusion and improve overall patient safety.
What's popularly called the "One Brand – One Formulation" proposal is, in CDSCO's own terms, a stakeholder consultation — not a published draft rule or final regulation. CDSCO issued a notice on 6 July 2026 inviting comments on brand name extensions, following a Drugs Consultative Committee recommendation, with feedback due by 17 July 2026. No specific draft provisions or implementation timeline have been released yet. Pharmaceutical companies should treat this as an early-stage consultation and continue monitoring official CDSCO updates.
Keeping track of regulatory updates can be challenging for pharmaceutical companies, especially when proposed changes may affect product approvals, branding, and future compliance obligations. PSR Compliance helps businesses stay informed about CDSCO regulations and provides professional guidance for pharmaceutical compliance requirements.
Our services include:
Our experts help pharmaceutical businesses understand evolving regulations and prepare for future compliance requirements with confidence.
The CDSCO draft proposal on regulating pharmaceutical brand name extensions is an important step towards improving patient safety and reducing medication errors caused by confusingly similar medicine names. By encouraging clearer branding practices, the regulator aims to make medicine identification easier for doctors, pharmacists, and patients.
Although the proposal is still under consultation, pharmaceutical companies should begin reviewing their branding strategies and stay informed about future CDSCO announcements. Businesses that prepare early and monitor regulatory developments closely will be better positioned to adapt if the proposal is finalized in the future.
It is a draft proposal to regulate the use of similar brand names for different drug formulations.
No, it is currently a draft proposal and has not yet become a final regulation.
The proposal aims to reduce medication errors and improve patient safety caused by confusingly similar drug names.
It is the practice of using an existing brand name with different suffixes for different medicines.
Manufacturers, marketers, generic medicine companies, and businesses launching new branded medicines may be affected.
The official draft proposal does not yet clarify how existing approved brands will be treated.
Examples include adding suffixes such as DSR, AM, H, XT, Plus, or Forte to an existing brand name.
They can increase the risk of prescribing, dispensing, or purchasing the wrong medicine.
Companies should review their branding strategy and monitor future CDSCO notifications.
Comments were invited by CDSCO through the public consultation process before 17 July 2026.
The main objective is to improve medicine identification and strengthen patient safety.
PSR Compliance provides CDSCO regulatory consulting, licensing assistance, documentation support, and pharmaceutical compliance services.
Book your free consultation with our specialists today.
PSR Assistant